| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Mangoceuticals, Inc.
$0.48
+0 (+1.03%)
Market Cap
10.36 M
EPS
-0.70
P/E Ratio
-
Value Trade
2.80 M
3.53 %
Week
22.92 %
1 Month
2.23 %
3 Month
42.16 %
6 Month
-99.28 %
5 Year
-99.28 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.10 M
52 Week Range
0.16 - 2.75
% held by Insiders
11.93 %
% held by Institutions
5.62 %
Enterprise Value
10.13 M
Total Shares
21.57 M
Short %
2.75 %
Float Shares
18.99 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | avian influenza in poultry | Phase 1 | 2025-02-12 | significant efficacy in reducing lung viral load | Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution Read More | |
— | avian influenza in poultry | Phase 1 | 2025-02-12 | significant efficacy in reducing lung viral load | Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution Read More | |
— | avian influenza in poultry | Phase 1 | 2025-02-12 | significant efficacy in reducing lung viral load | Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution Read More |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MGRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MGRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MGRX▲ +1%today
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Mangoceuticals, Inc. has secured a $2.5 million investment for its subsidiary, MangoRx IP Holdings, aimed at advancing its antiviral intellectual property portfolio. The initial tranche of $1.75 million has been received, allowing the company to pursue commercialization without issuing new shares of common stock. This investment is expected to strengthen MangoRx IP's position in various markets, including oral care and livestock feed.
Read more →MGRXMangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Mangoceuticals, Inc. has filed a civil lawsuit against Clarity Ventures, Inc. for over $73 million, alleging failure to deliver a functional ERP and eCommerce platform. Clarity has countered with claims of unpaid invoices. Despite the lawsuit, Mangoceuticals has developed its own telehealth platform, which has improved its operational performance.
Read more →MGRXMangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innova
Read more →MGRXMangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovat
Read more →MGRX▲ +18.8%on this news· ran to +30% by day 1
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
Mangoceuticals, Inc. has successfully closed a $2.5 million registered direct offering and private placement with institutional investors. The transactions involved the issuance of common stock and warrants, with proceeds expected to be used for corporate purposes. The offering was conducted in compliance with SEC regulations.
Read more →MGRX▼ -45.6%on this newsshared move
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
Mangoceuticals, Inc. has announced a partnership with Cube Group to launch a Solana-focused digital asset treasury strategy worth up to $100 million. This initiative aims to enhance shareholder value through high-yield opportunities and positions the company for growth in the digital asset sector. The strategy emphasizes risk management and aims to capitalize on the Solana ecosystem's potential.
Read more →MGRX▲ +7.4%on this news· ran to -42% by day 1shared move
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today an
Read more →MGRX▲ +24.4%on this news
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…
Read more →MGRX▼ -32.4%on this newsshared move
Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management
Mangoceuticals has partnered with Eli Lilly and Novo Nordisk to offer direct access to GLP-1 medications Zepbound and Wegovy for obesity management. Through its telehealth platform, customers can receive personalized treatment plans and ongoing support. The initiative aligns with government efforts to reduce medication costs, aiming to provide affordable solutions for weight management.
Read more →MGRX▲ +11.8%on this news· ran to +29% by day 3
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
Mangoceuticals, Inc. announced promising results from studies on its antiviral compound MGX-0024, which demonstrated 100% respiratory survival in chickens. Conducted in India, the studies showed a significant reduction in mortality from respiratory diseases. The company is working towards regulatory approvals and scaling production for MGX-0024, aiming to provide a safe, antibiotic-free solution for poultry health.
Read more →MGRX▼ -13.8%on this news
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
Mangoceuticals Inc. has announced its acquisition of Smokeless Technology Corp., expanding into the rapidly growing oral pouch delivery market. This strategic move aims to integrate stimulant formulations with existing product lines under MangoRx and PeachesRx. The company has also appointed Tim Corkum, a former Philip Morris executive, to lead this new division, enhancing its management capabilities.
Read more →MGRX▼ -40.8%on this news
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
Mangoceuticals, Inc. has entered a Master Distribution Agreement to exclusively market Diabetinol® in the U.S. and Canada. This plant-based nutraceutical, derived from citrus peel, has shown promising results in improving insulin sensitivity and metabolic health. The company aims to address the growing diabetes crisis by providing a more affordable option for those unable to access conventional therapies.
Read more →MGRX▼ -15.7%on this news· ran to -27% by day 3
Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Mangoceuticals has launched PeachesRx, a telehealth brand focused on women's health and wellness. The brand will initially offer GLP-1 receptor agonists for weight loss, catering to the increasing demand among women. With a secure telemedicine platform, PeachesRx aims to provide personalized healthcare solutions, positioning itself as a leader in the women's telehealth market.
Read more →MGRXMangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
Mangoceuticals, Inc. is advancing its antiviral research targeting avian influenza in poultry using a patented water-based solution. The company has engaged Vipragen Biosciences for efficacy studies, building on promising Phase I results. This non-pharmaceutical approach aims to reduce costs and improve biosecurity in poultry farming amidst ongoing avian flu outbreaks.
Read more →MGRX▲ +7.9%on this news· ran to +39% by day 3
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
Mangoceuticals, Inc. has reported significant progress in its H1N1 efficacy study, showing a notable reduction in viral load. The company is now advancing to the next research phase and engaging Vipragen Biosciences to establish a cohort for H5N1 studies. This dual approach underscores the potential of their patented respiratory illness prevention technology.
Read more →MGRXMangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
Mangoceuticals, Inc. has signed an exclusive distribution agreement with Propre Energie for Dermytol®, a clinically proven skincare treatment targeting hyperpigmentation. Dermytol® is noted for its plant-based formula that reduces melanin production more effectively than traditional agents like Kojic acid. This partnership aims to leverage Mangoceuticals' marketing expertise to enhance Dermytol®'s presence in North and South America.
Read more →MGRXMangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced the acquisition of patent
Read more →MGRXMangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced that it has launched an i
Read more →MGRXMangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced that the Company recei
Read more →MGRXMANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight lo
Read more →MGRX▼ -8%on this news
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weigh
Read more →MGRX▲ +7%on this news
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight
Read more →MGRXMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and horm
Read more →MGRXMangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
Provides MangoRx with entrance into the non-Rx based, nutraceutical product space for sales on both direct-to-consumer online platforms and through retail locations Dallas, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”)
Read more →MGRX▼ -9.9%on this news
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “
Read more →MGRX▼ -41%on this news
Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering
Dallas, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely fo
Read more →MGRXMangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America
Tapping into a market of more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico in 2024 and fueling International Sales Access Across Latin America Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “
Read more →MGRX▲ +17.6%on this news
Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider
TRYBE Labs to provide MangoRx customers with turnkey at-home blood collection services and solutions Dallas, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a varie
Read more →MGRX▼ -10.8%on this news· ran to -22% by day 3
Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men’s Health Awareness Month
Dallas, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely fo
Read more →MGRX▲ +8.6%on this news
Mangoceuticals Launches TikTok Influencer Initiative and Becomes the Presenting Sponsor of the Only Stans Podcast with Glenny Balls
Announcement follows launch of Affiliate Program to Drive Further Awareness and Growth Dallas, Texas, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s heal
Read more →MGRX▲ +25%on this news· ran to +42% by day 1
Mangoceuticals, Inc. Provides Update to Shareholders on Q3 Achievements and Guidance on Year End and Near-Term Initiatives
Dallas, Texas, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business
Dallas, Texas, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRX▼ -8%on this newsshared move
Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth
Dallas, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals Brand MangoRx Announced as Raindance Film Festival’s Headline Sponsor
The London-Based International Film Festival Will Feature the MangoRx Short Film Competition Focused on Mental Health and Erectile Dysfunction Dallas, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on
Read more →MGRXMangoceuticals Expands its Nationwide Marketing Efforts with a Multiplatform Audio Powerhouse Across America
Expanded Celebrity Podcast Marketing Campaign to involve Fly on the Wall with David Spade and Dana Carvey, The Monday Morning Podcast with Bill Burr, and The Dale Jr Download with Dale Earnhardt Jr., WFAN Sports Radio and more! Dallas, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- M
Read more →MGRXMangoceuticals Launches New High-Production Quality Ad Providing Fresh Insight into its Proprietary Mango Erectile Dysfunction Pill Formula
Dallas, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve
Dallas, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely for
Read more →MGRXMangoceuticals Partners with Greater NY Chamber of Commerce for Mass Marketing & Sales of Flagship Mango Product
MangoRx enters the NY market with the full force of the GNYCC with over 30,000+ business & civic leaders who represent the backbone of the Greater New York area Dallas, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a co
Read more →MGRXMangoceuticals, Inc. Names Award Winning Globally Recognized Lucky Break PR as Public Relations Firm
Dallas, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRX▲ +28.3%on this newsshared move
Mangoceuticals Engages Premier Global Software Development Firm, RedLime Solutions to Expand Technology Platform to Accommodate Increased Customer Flow
Dallas, Texas, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRX▼ -5.2%on this news· ran to +25% by day 3shared move
Mangoceuticals, Inc. Adds Top Men’s Podcast, Pillow Talk with Ryan Pownall, to Sponsorship Portfolio
Dallas, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement
Dallas, Texas, July 18, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals, Inc. Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Fox Business, Bloomberg TV, and Newsmax TV
Dallas, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRX▼ -5.4%on this news
Mangoceuticals Launches “Make America Hard Again” Campaign & Merchandise Website
Dallas, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRX▲ +9.9%on this newsshared move
Mangoceuticals CEO to Feature in Upcoming Interview at Nasdaq MarketSite Studio on Fox Business, Bloomberg TV, and Newsmax TV
MGRX’s CEO, Jacob Cohen returns to the Nasdaq MarketSite Studio to begin filming a Multi-Part TV Series with New to The Street discussing MangoRx Dallas, Texas, June 22, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused o
Read more →MGRXMangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product
Dallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely for
Read more →MGRX▼ -6.1%on this newsshared move
Mangoceuticals, Inc. Signs Sponsorship Agreement with GaS Digital Network to Promote Mango Across Multiple Hardcore Comedy Podcasts
Mangoceuticals continues to increase its marketing of Mango & corporate visibility, jointing many well-known podcasts in the epicenter of uncensored and unfiltered comedy Dallas, Texas, June 15, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Compa
Read more →MGRX▲ +10.8%on this news
Mangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” Podcast
Dallas, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely form
Read more →MGRXMangoceuticals Adds Renowned Tech Entrepreneur and Investor, Aaron Andrew, to Advisory Board
Dallas, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formu
Read more →MGRXMangoceuticals to Ring NASDAQ Stock Market Closing Bell on May 18
DALLAS, TX, May 18, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formula
Read more →MGRXMangoceuticals Launches New “Some Things Are Better Hard” Viral Video Ad Campaign
DALLAS, TX, May 11, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formula
Read more →Competitive Position
How MGRX ranks across every disease it competes inCompetitive Position is a premium feature
See how MGRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial